ArticleCureus2025
Real-World Evidence Demonstrating Nemolizumab's Rapid Efficacy in Recalcitrant Uremic Pruritus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uremic pruritus is a common and distressing condition in patients with advanced chronic kidney disease (CKD). It often leads to disruption of sleep habits, impaired mental health, and reduced quality of life. Nemolizumab is an interleukin-31 receptor subunit alpha (IL-31R𝛼) antagonist that is currently approved to treat prurigo nodularis (PN) and atopic dermatitis (AD). However, its effectiveness in treating uremic pruritus remains uncertain, as it has only been explored in a limited number of small studies. We present a case of a 69-year-old man on long-term hemodialysis who presented with refractory uremic pruritus. The patient initially reported a pruritus numerical rating scale (NRS) score of 8 out of 10, indicating severe itch on a scale where 0 represents no itch and 10 represents the worst itch imaginable. Despite adequate six-week trials of triamcinolone acetonide 0.1% ointment twice daily, narrowband ultraviolet B (NB-UVB) phototherapy three times weekly, N-acetylcysteine (600 mg twice daily), and gabapentin (300 mg three times daily), his debilitating itch persisted. Consequently, treatment with nemolizumab was initiated. Just two weeks after the initial dose, the patient reported an NRS score of 0, indicating complete relief from pruritus, along with a reduction in excoriated lesions observed on physical examination. The patient reported no side effects from nemolizumab. This case highlights the potential of nemolizumab as an effective and safe treatment option for recalcitrant uremic pruritus. Further exploration of its therapeutic applications in this condition and other vexing-to-treat pruritic conditions is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.